The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2022 | Integration of radiology, pathology, & genomics for prediction of response to anti-PD-1 in NSCLC
Jia Luo, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the development of a multimodal biomarker to predict immunotherapy response in patients with non–small cell lung cancer (NSCLC). A cohort of 247 patients who have received immunotherapy as well have complete radiology, pathology, genomics, and clinical data was assessed and the multimodal model based on the aforementioned factors improved the prediction of therapy response. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
